Literature DB >> 24339215

Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.

Sarah Ringold1, Pamela F Weiss, Robert A Colbert, Esi Morgan DeWitt, Tzielan Lee, Karen Onel, Sampath Prahalad, Rayfel Schneider, Susan Shenoi, Richard K Vehe, Yukiko Kimura.   

Abstract

OBJECTIVE: There is no standardized approach to the initial treatment of polyarticular juvenile idiopathic arthritis (JIA) among pediatric rheumatologists. Understanding the comparative effectiveness of the diverse therapeutic options available will result in better health outcomes for polyarticular JIA. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans (CTPs) for use in clinical practice to facilitate such studies.
METHODS: A case-based survey was administered to CARRA members to identify the common treatment approaches for new-onset polyarticular JIA. Two face-to-face consensus conferences employed modified nominal group technique to identify treatment strategies, operational case definition, end points, and data elements to be collected. A core workgroup reviewed the relevant literature, refined plans, and developed medication dosing and monitoring recommendations.
RESULTS: The initial case-based survey identified significant variability among treatment approaches for new-onset polyarticular JIA. We developed 3 CTPs based on treatment strategies for the first 12 months of therapy, as well as case definitions and clinical and laboratory monitoring schedules. The CTPs include a step-up plan (nonbiologic disease-modifying antirheumatic drug [DMARD] followed by a biologic DMARD), an early combination plan (nonbiologic and biologic DMARD combined within a month of treatment initiation), and a biologic only plan. This approach was approved by 96% of the CARRA JIA Research Committee members attending the 2013 CARRA face-to-face meeting.
CONCLUSION: Three standardized CTPs were developed for new-onset polyarticular JIA. Coupled with data collection at defined intervals, use of these CTPs will enable the study of their comparative effectiveness in an observational setting to optimize initial management of polyarticular JIA.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24339215      PMCID: PMC4467832          DOI: 10.1002/acr.22259

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  27 in total

1.  Incidence of childhood type 1 diabetes worldwide. Diabetes Mondiale (DiaMond) Project Group.

Authors:  M Karvonen; M Viik-Kajander; E Moltchanova; I Libman; R LaPorte; J Tuomilehto
Journal:  Diabetes Care       Date:  2000-10       Impact factor: 19.112

2.  Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference.

Authors:  Adam M Huber; Angela B Robinson; Ann M Reed; Leslie Abramson; Sharon Bout-Tabaku; Ruy Carrasco; Megan Curran; Brian M Feldman; Harry Gewanter; Thomas Griffin; Kathleen Haines; Mark F Hoeltzel; Josephine Isgro; Philip Kahn; Bianca Lang; Patti Lawler; Bracha Shaham; Heinrike Schmeling; Rosie Scuccimarri; Michael Shishov; Elizabeth Stringer; Julie Wohrley; Norman T Ilowite; Carol Wallace
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-04       Impact factor: 4.794

3.  Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.

Authors:  D J Lovell; E H Giannini; A Reiff; G D Cawkwell; E D Silverman; J J Nocton; L D Stein; A Gedalia; N T Ilowite; C A Wallace; J Whitmore; B K Finck
Journal:  N Engl J Med       Date:  2000-03-16       Impact factor: 91.245

4.  Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations.

Authors:  Sarah Ringold; Kristy D Seidel; Thomas D Koepsell; Carol A Wallace
Journal:  Rheumatology (Oxford)       Date:  2009-06-17       Impact factor: 7.580

5.  Development and validation of a composite disease activity score for juvenile idiopathic arthritis.

Authors:  Alessandro Consolaro; Nicolino Ruperto; Anna Bazso; Angela Pistorio; Silvia Magni-Manzoni; Giovanni Filocamo; Clara Malattia; Stefania Viola; Alberto Martini; Angelo Ravelli
Journal:  Arthritis Rheum       Date:  2009-05-15

6.  Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia.

Authors:  M L Garré; M V Relling; D Kalwinsky; R Dodge; W R Crom; M Abromowitch; C H Pui; W E Evans
Journal:  J Pediatr       Date:  1987-10       Impact factor: 4.406

7.  Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial.

Authors:  Nicolino Ruperto; Daniel J Lovell; Pierre Quartier; Eliana Paz; Nadina Rubio-Pérez; Clovis A Silva; Carlos Abud-Mendoza; Ruben Burgos-Vargas; Valeria Gerloni; Jose A Melo-Gomes; Claudia Saad-Magalhães; Flavio Sztajnbok; Claudia Goldenstein-Schainberg; Morton Scheinberg; Immaculada Calvo Penades; Michael Fischbach; Javier Orozco; Philip J Hashkes; Christine Hom; Lawrence Jung; Loredana Lepore; Sheila Oliveira; Carol A Wallace; Leonard H Sigal; Alan J Block; Allison Covucci; Alberto Martini; Edward H Giannini
Journal:  Lancet       Date:  2008-07-14       Impact factor: 79.321

8.  In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome.

Authors:  M A Peeters; M O Rethore; J Lejeune
Journal:  Br J Haematol       Date:  1995-03       Impact factor: 6.998

9.  Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.

Authors:  Daniel J Lovell; Nicolino Ruperto; Steven Goodman; Andreas Reiff; Lawrence Jung; Katerina Jarosova; Dana Nemcova; Richard Mouy; Christy Sandborg; John Bohnsack; Dirk Elewaut; Ivan Foeldvari; Valeria Gerloni; Jozef Rovensky; Kirsten Minden; Richard K Vehe; L Wagner Weiner; Gerd Horneff; Hans-Iko Huppertz; Nancy Y Olson; John R Medich; Roberto Carcereri-De-Prati; Melissa J McIlraith; Edward H Giannini; Alberto Martini
Journal:  N Engl J Med       Date:  2008-08-21       Impact factor: 91.245

10.  Time to share.

Authors:  Nico M Wulffraat; Bas Vastert
Journal:  Pediatr Rheumatol Online J       Date:  2013-02-15       Impact factor: 3.054

View more
  39 in total

1.  Infliximab therapy and outcomes in patients with polyarticular juvenile idiopathic arthritis: a single-center study in China.

Authors:  Da-Wei Liu; Jiao-Jiao Chen; Xue-Mei Tang; Yu Zhang; Juan Zhou
Journal:  World J Pediatr       Date:  2019-10-14       Impact factor: 2.764

Review 2.  Management of juvenile idiopathic arthritis: hitting the target.

Authors:  Claas Hinze; Faekah Gohar; Dirk Foell
Journal:  Nat Rev Rheumatol       Date:  2015-01-06       Impact factor: 20.543

3.  Paediatric rheumatic disease: Treatment of JIA in the biologic era: what are we waiting for?

Authors:  Taunton R Southwood
Journal:  Nat Rev Rheumatol       Date:  2014-02-11       Impact factor: 20.543

4.  Power in numbers.

Authors:  Evelyne Vinet; Eliza F Chakravarty; Megan E B Clowse
Journal:  Rheumatology (Oxford)       Date:  2018-07-01       Impact factor: 7.580

5.  The challenge of trial design in paediatric rheumatology.

Authors:  Tim Niehues
Journal:  Nat Rev Rheumatol       Date:  2016-04       Impact factor: 20.543

6.  Moving towards optimal therapy in paediatric rheumatology.

Authors:  Jay Mehta
Journal:  Nat Rev Rheumatol       Date:  2016-04       Impact factor: 20.543

Review 7.  Improving care delivery and outcomes in pediatric rheumatic diseases.

Authors:  Julia G Harris; Catherine A Bingham; Esi M Morgan
Journal:  Curr Opin Rheumatol       Date:  2016-03       Impact factor: 5.006

Review 8.  Biologics in juvenile idiopathic arthritis: a narrative review.

Authors:  Federica Vanoni; Francesca Minoia; Clara Malattia
Journal:  Eur J Pediatr       Date:  2017-07-20       Impact factor: 3.183

Review 9.  Glucocorticoid treatment in juvenile idiopathic arthritis.

Authors:  Ezgi Deniz Batu
Journal:  Rheumatol Int       Date:  2018-10-01       Impact factor: 2.631

Review 10.  Consensus Treatment Plans for Chronic Nonbacterial Osteomyelitis Refractory to Nonsteroidal Antiinflammatory Drugs and/or With Active Spinal Lesions.

Authors:  Yongdong Zhao; Eveline Y Wu; Melissa S Oliver; Ashley M Cooper; Matthew L Basiaga; Sheetal S Vora; Tzielan C Lee; Emily Fox; Gil Amarilyo; Sara M Stern; Jeffrey A Dvergsten; Kathleen A Haines; Kelly A Rouster-Stevens; Karen B Onel; Julie Cherian; Jonathan S Hausmann; Paivi Miettunen; Tania Cellucci; Farzana Nuruzzaman; Angela Taneja; Karyl S Barron; Matthew C Hollander; Sivia K Lapidus; Suzanne C Li; Seza Ozen; Hermann Girschick; Ronald M Laxer; Fatma Dedeoglu; Christian M Hedrich; Polly J Ferguson
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-07-12       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.